Real-World Retrospective Study of Clinical and Economic Outcomes Among Patients with Locally Advanced or Metastatic Urothelial Carcinoma Treated with First-Line Systemic Anti-Cancer Therapies in the United States: Results from the IMPACT UC-III Study
Rattachement africain : us, de. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
This retrospective cohort study evaluated characteristics, treatment patterns, and clinical outcomes in adults with locally advanced/metastatic urothelial carcinoma (la/mUC) receiving first-line (1L) systemic treatment with or without avelumab 1L maintenance (1LM) between January 2020 and July 2023. The index date was the first date with a claim for 1L systemic therapy after a la/mUC diagnosis. Patients with continuous health plan enrollment for ≥6 months before and ≥1 month after the index date were identified from Carelon Research's Healthcare Integrated Research Database. Of 2820 patients receiving 1L treatment, 37.0% received platinum-based chemotherapy (PBC); 39.0%, immuno-oncology (IO) monotherapy; and 24.0%, other therapies. Renal disease and other comorbidities influenced 1L regimen choice. Healthcare resource utilization (HCRU) and costs were reported for patients receiving second-line (2L) treatment. HCRU was high in 32.8% of patients (926 of 2820) who received 2L treatment. Median all-cause direct medical costs per patient per month were USD 15,859, USD 19,781, USD 11,346, and USD 9516 for 1L PBC, 1L PBC + avelumab 1LM, 1L IO monotherapy, and 1L other therapies, respectively. Most direct healthcare costs were attributed to all-cause outpatient visits.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Real-World Retrospective Study of Clinical and Economic Outcomes Among Patients with Locally Advanced or Metastatic Urothelial Carcinoma Treated with First-Line Systemic Anti-Cancer Therapies in the United States: Results from the IMPACT UC-III Study
- Date Crossref
- 02/07/2025
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Kaiser Permanente Riverside Medical Center pays non établi dans la noticeÉtablissement de santé
-
Ono Pharmaceutical (United States) pays non établi dans la noticeEntreprise
-
Merck Healthcare KGaA pays non établi dans la noticeEntreprise
-
Wilmington University pays non établi dans la noticeUniversité ou école supérieure
-
Merck KGaA pays non établi dans la noticeEntreprise
-
Kaiser Permanente Southern California pays non établi dans la noticeInstitution
-
Inc. EMD Serono pays non établi dans la noticeEntreprise
-
Carelon Research pays non établi dans la noticeInstitution
Kaiser Permanente Riverside Medical Center, Ono Pharmaceutical (United States) et Merck Healthcare KGaA, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.